Elory Leonard
Doktorand
E-postadress: elory.leonard@ki.se
Besöksadress: NEO Medicinaren 25, HERM plan 7, Hälsovägen 7C (lastkaj), 14157 Huddinge/Stockholm
Postadress: H7 Medicin, Huddinge, H7 Hematologi Qian, 171 77 Stockholm
Artiklar
- Article: NATURE COMMUNICATIONS. 2024;15(1):7966
- Article: SCIENTIFIC REPORTS. 2023;13(1):21787
- Journal article: BLOOD. 2023;142:2707
- Article: JOURNAL OF EXPERIMENTAL MEDICINE. 2023;220(10):e20220953
- Article: BLOOD. 2023;142(1):73-89
Alla övriga publikationer
- Preprint: BIORXIV. 2022
Anställningar
- Doktorand, Medicin, Huddinge, Karolinska Institutet, 2024-2025
Konferenser och events
- Poster-presentationer av egna accepterade abstract, European School of Hematology 5th Scientific Workshop: the Haematological Tumour Microenvironment and its Therapeutic Targeting in London, UK, https://www.esh.org/conference/5th-scientific-workshop-the-haematological-tumour-microenvironment-and-its-therapeutic-targeting/, "Human skin mesenchymal stem cells provide a unique niche for acute myeloid leukemia-initiating stem cells", 2025
- Poster-presentationer av egna accepterade abstract, 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California, USA, https://www.hematology.org/meetings/annual-meeting, "Protective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells", 2023
- Muntliga presentationer av egna accepterade abstract, European School of Hematology 4th Scientific Workshop: the Haematological Tumour Microenvironment and its Therapeutic Targeting in London, UK, https://www.esh.org/conference/4th-scientific-workshop-the-haematological-tumour-microenvironment-and-its-therapeutic-targeting/, "A Mesenchymal Cell Niche in Skin for Extramedullary Acute Myeloid Leukemia", 2023
- Muntliga presentationer av egna accepterade abstract, XIXth Karolinska Institutet Cancer Research Retreat, Djurönäset, Stockholm, https://ki.se/en/cancer-research-ki/the-xxth-cancer-research-ki-retreat, "The impact of mesenchymal niche in human skin on drug response of acute myeloid leukemia (AML)", 2022